Oculis (NASDAQ:OCS) Price Target Raised to $32.00 at HC Wainwright

Oculis (NASDAQ:OCS - Get Free Report) had its price target boosted by HC Wainwright from $29.00 to $32.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 80.89% from the company's current price.

A number of other brokerages have also weighed in on OCS. Robert W. Baird boosted their target price on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research report on Thursday, March 13th. Chardan Capital reaffirmed a "buy" rating and set a $28.00 target price on shares of Oculis in a report on Thursday, April 17th.

Oculis Stock Down 2.4 %

OCS stock traded down $0.43 during trading on Thursday, hitting $17.69. 8,031 shares of the stock traded hands, compared to its average volume of 46,269. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The stock has a market cap of $772.38 million, a price-to-earnings ratio of -9.17 and a beta of 0.19. Oculis has a 1 year low of $10.79 and a 1 year high of $23.08. The firm's 50 day moving average is $18.76 and its two-hundred day moving average is $18.09.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, sell-side analysts anticipate that Oculis will post -2.09 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. abrdn plc boosted its stake in shares of Oculis by 23.0% in the fourth quarter. abrdn plc now owns 1,009,424 shares of the company's stock worth $17,150,000 after acquiring an additional 188,871 shares during the period. Bank of America Corp DE boosted its stake in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares during the period. Citadel Advisors LLC bought a new stake in shares of Oculis during the fourth quarter valued at approximately $389,000. Bellevue Group AG purchased a new position in shares of Oculis in the fourth quarter worth $170,000. Finally, Geode Capital Management LLC boosted its position in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 22.30% of the company's stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.